Walter L. Longo, MD

Publications

• Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.

  (Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS.) J Clin Oncol. 2025 Jul 10;43(20):2285-2295 PMID: 40163793 SCOPUS ID: 2-s2.0-105010720202 03/31/2025

• Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation.

  (Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M.) Transplant Cell Ther. 2024 Dec;30(12):1191.e1-1191.e8 PMID: 39303985 PMCID: PMC12483827 SCOPUS ID: 2-s2.0-85206435293 09/21/2024

• Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.

  (Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M.) Blood Adv. 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024

• Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.

  (Mohan, M., S. Nagavally, N.N. Shah, L. Michaelis, S. Chhabra, A.D. Souza, S. Abedin, L. Runaas, G.S. Guru Murthy, W. Longo, M. Hamadani, B. Dhakal, P. Hari, and T.S. Fenske .) Clin Lymphoma Myeloma Leuk. 22(7): p. e495-e497 02/14/2025

• Severity arid organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation.

  (Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. .) Bone Marrow Transplant. 59(3):373-379 02/14/2025

• Adaptive Manufacturing of LV20.19 CART-Cells for Relapsed, Refractory Mantle Cell Lymphoma

  (Shah, N.N., F. Furqan, A. Szabo, T. Kearl, A. Zamora, J. Neumann, P.N. Hari, D. Schneider, W. Longo, P. Hematti, B.D. Johnson, M. Hamadani, and T.S. Fenske.) Blood. 142(Supplement 1): p. 1024-1024. ORAL 02/14/2025

• Phase I Trial ofLV20.19 CART-Cells for Relapsed, Refractory CLL and Richter's Transformation

  (Shah, N.N., E.L. Atallah, S. Abedin, G.S.G. Murthy, L. Runaas, L.C. Michaelis, W. Longo, F. Furqan, D. Bucklan, A. Szabo, T. Kearl, D. Schneider, K. Palen, B.D. Johnson, P. Hematti, T.S. Fenske, and M. Hamadani.) Transplantation and Cellular Therapy. 30(2, Supplement): p. S35-S36. ORAL 02/14/2025

• Severity of Cytokine Release Syndrome As a Predictor of Infections after T-Cell Replete Haploidentical Hematopoietic Cell Transplantation (haploHCT)

  (Abid, M.B., A. Szabo, M. Hamadani, M.B. Graham, P. Hari, J. Jerkins, N.N. Shah, S. Abedin, L. Runaas, W.L. Longo, and S. Chhabra.) Biology of Blood and Marrow Transplantation. 25(3): p. S368. POSTER 02/14/2025

• Clinical Characteristics and Patient Outcomes with HLH-like Toxicities after CDl 9 Based CART-Cell Therapy.

  (Furqan, F., E. Aschenbrenner, J. Talano, A. Moskop, W. Longo, B.D. Johnson, T.S. Fenske, M. Hamadani, and N.N. Shah .) Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy. 29(2): p. S131-S132. POSTER 02/14/2025

• Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

  (Shah, N.N., P.L. Zinzani, M.L. Wang, S.D. Nasta, E. Lech-Maranda, Y. Ogawa, B. Fakhri, B. Kuss, K. Miyashita, K. Patel, C.C. Coombs, S. Ma, M. Patel, M.A. Barve, B. Tessoulin, A. Stathis, W.S. Kim, D. Ennishi, D. Hashimoto, K. Kojima, A.D. Zelenetz, J.B. Cohen, J.M. Vose, K.J. Maddocks, T. Munir, F. Sun, F. Bian, D.E. Tsai, P. Abada, and C.Y. Cheah.) Blood. 142(Supplement 1): p. 3026-3026. POSTER 02/14/2025

• Outpatient Administration of Commercial antiCD19 and Antibcma Chimeric Antigen Receptor-Modified T-Cell (CAR-T) Therapies Using a Strategy ofNo Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention.

  (Furqan, F., V. Bhatlapeumarthi, F. Farrukh, T.S. Fenske, W. Longo, N.N. Shah, A.D Souza, M.C. Pasquini, G.S.G. Murthy, L. Runaas, S. Abedin, M. Mohan, B. Dhakal, and M. Hamadani.) Transplantation and Cellular Therapy. 30(2, Supplement): p. S211. POSTER 02/14/2025

• Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD 19 (LV20.19) CART-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma

  (Furqan, F., K. Palen, B.D. Johnson, T. Kearl, P. Hematti, W. Longo, M. Hamadani, T. Fenske, and N.N. Shah.) Journal of Clinical Oncology. 42(suppl 16; abstr 7043). POSTER 02/14/2025